Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 6 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Intellia Therapeutics Inc | NTLA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 23.00 | 04:24:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 23.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 6 | - | 19.37 - 47.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 05:03:52 | 1 | $ 23.15 | USD |
Intellia Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.21B | 96.11M | - | 36.28M | -481.19M | -5.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Intellia Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NTLA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 22.80 | 24.99 | 22.37 | 23.49 | 1,295,791 | 0.20 | 0.88% |
| 1 Month | 25.30 | 25.53 | 19.37 | 22.43 | 1,244,558 | -2.30 | -9.09% |
| 3 Months | 27.95 | 34.87 | 19.37 | 26.73 | 1,467,930 | -4.95 | -17.71% |
| 6 Months | 28.50 | 34.87 | 19.37 | 27.54 | 1,512,123 | -5.50 | -19.30% |
| 1 Year | 42.50 | 47.48 | 19.37 | 31.09 | 1,241,602 | -19.50 | -45.88% |
| 3 Years | 67.95 | 202.73 | 19.37 | 65.36 | 1,230,644 | -44.95 | -66.15% |
| 5 Years | 16.00 | 202.73 | 9.18 | 55.64 | 1,101,389 | 7.00 | 43.75% |
Intellia Therapeutics Description
| Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
